Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells.
In human proximal tubules, organic cations are taken up from blood into cells by human organic cation transporter 2 [hOCT2/solute carrier (SLC) 22A2] and then eliminated into the lumen by apical H(+)/organic cation antiporters, human multidrug and toxin extrusion 1 (hMATE1/SLC47A1) and hMATE2-K (SLC47A2). To evaluate drug interactions of cationic drugs in the secretion process, epithelial cells engineered to express both hOCT2 and hMATE transporters are required to simultaneously evaluate drug interactions with renal basolateral and apical organic cation transporters. In the present study, therefore, we assessed the drug interaction between cimetidine and metformin with double-transfected Madin-Darby canine kidney cells stably expressing both hOCT2 and hMATE1 as an in vitro model of the proximal tubular epithelial cells. The basolateral-to-apical transport and intracellular accumulation of [(14)C]metformin by a double transfectant were markedly inhibited by 1 mM cimetidine at the basolateral side. On the other hand, 1 microM cimetidine at the basolateral side moderately decreased the basolateral-to-apical transport of [(14)C]metformin and significantly increased the intracellular accumulation of [(14)C]metformin from the basolateral side, suggesting that cimetidine at a low concentration inhibits apical hMATE1, rather than basolateral hOCT2. Actually, in concentration-dependent inhibition studies by a single transporter expression system, such as human embryonic kidney 293 stably expressing hMATE1, hMATE2-K, or hOCT2, cimetidine showed higher affinity for hMATEs than for hOCT2. These results suggest that apical hMATE1 is involved in drug interactions between cimetidine and cationic compounds in the proximal tubular epithelial cells.
Tsuda
Masahiro
M
Department of Pharmacy, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan.
Terada
Tomohiro
T
Ueba
Miki
M
Sato
Tomoko
T
Masuda
Satohiro
S
Katsura
Toshiya
T
Inui
Ken-ichi
K
D000818:Animals; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D048429:Cell Size; D002927:Cimetidine / Q000494:pharmacology*; D022162:Cytoplasmic Vesicles / Q000187:drug effects / Q000378:metabolism; D004285:Dogs; D004847:Epithelial Cells / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007668:Kidney / Q000166:cytology / Q000187:drug effects*; D008687:Metformin / Q000494:pharmacology*; D027701:Organic Cation Transport Proteins / Q000235:genetics* / Q000378:metabolism*; D000075102:Organic Cation Transporter 2; D014162:Transfection
D006635:Histamine H2 Antagonists; D007004:Hypoglycemic Agents; D027701:Organic Cation Transport Proteins; D000075102:Organic Cation Transporter 2; C491013:SLC22A2 protein, human; C521869:SLC47A1 protein, human; D002927:Cimetidine; D008687:Metformin